- Cancer drugmaker
- Incyte's stock was down as much as 22% before markets opened on Friday morning, while Merck's was down a little more than 1%.
- Cancer immunotherapy works by harnessing the body's immune system to treat cancer.
- The trial was looking to see if combining two drugs — Merck's PD1 checkpoint inhibitor and Incyte's IDO1 inhibitor — that both essentially take the brake off the immune system to go after the cancer cells in people with metastatic melanoma could work even better than Merck's drug alone.
ADVERTISEMENT
A cancer drugmaker just failed a key trial and its stock is crashing (INCY, MRK)
Cancer drugmaker Incyte said on Friday that a key trial combining its cancer immunotherapy drug with a blockbuster drug from Merck failed in a late-stage trial.
ADVERTISEMENT
Recommended articles
FOLLOW BUSINESS INSIDER AFRICA
ADVERTISEMENT
Recommended articles
10 least powerful African passports in 2024
Top 10 African countries with the largest labor force
Video footage of Asian man beating two Africans sparks racism comments online
East Africa’s future in energy shines brighter on the continent
Infinix NOTE 40 Series takes centre stage with all-round fastcharge 2.0
Here are the new causes of Nigeria’s inflation according to the CBN governor
Russian troops have entered base housing US military forces in Niger
Digitalisation: A revolution in financial services
